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The storage and use of glycogen, the main energy reserve in the brain, is a metabolic feature of astrocytes.
Glycogen synthesis is regulated by Protein Targeting to Glycogen (PTG), a member of speciﬁc glycogen-
binding subunits of protein phosphatase-1 (PPP1). It positively regulates glycogen synthesis through de-
phosphorylation of both glycogen synthase (activation) and glycogen phosphorylase (inactivation). In
cultured astrocytes, PTG mRNA levels were previously shown to be enhanced by the neurotransmitter
noradrenaline. To achieve further insight into the role of PTG in the regulation of astrocytic glycogen, its
levels of expression were manipulated in primary cultures of mouse cortical astrocytes using adenovirus-
mediated overexpression of tagged-PTG or siRNA to downregulate its expression. Infection of astrocytes
with adenovirus led to a strong increase in PTG expression and was associated with massive glycogen
accumulation (>100 fold), demonstrating that increased PTG expression is sufﬁcient to induce glycogen
synthesis and accumulation. In contrast, siRNA-mediated downregulation of PTG resulted in a 2-fold
decrease in glycogen levels. Interestingly, PTG downregulation strongly impaired long-term astrocytic
glycogen synthesis induced by insulin or noradrenaline. Finally, these effects of PTG downregulation on
glycogen metabolism could also be observed in cultured astrocytes isolated from PTG-KO mice. Collec-
tively, these observations point to a major role of PTG in the regulation of glycogen synthesis in astro-
cytes and indicate that conditions leading to changes in PTG expression will directly impact glycogen
levels in this cell type.
© 2016 The Authors. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glycogen is the main energy reserve in the central nervous
system (CNS) and is localized primarily in astrocytes (Magistretti
et al., 1993a). At the physiological level, the role of glycogen as an
energy reserve in energy deﬁciency has beenwell documented (see
e.g. Magistretti and Allaman, 2015 and references therein). More
recent evidence also points to an important role played by astro-
cytic glycogen in higher brain functions in mammals such as; GS, Glycogen synthase; GP,
lin.
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ss article under the CC BY-NC-ND llearning and memory (Boury-Jamot et al., 2016; Duran et al., 2013;
Gibbs, 2016; Newman et al., 2011; Obel et al., 2012; Suzuki et al.,
2011). In particular, an activity-dependent mobilization of
glycogen associated with astrocytic lactate production and transfer
to neurons is crucial for the establishment of long term memory in
rodents in an inhibitory avoidance learning paradigm (Gao et al.,
2016; Steinman et al., 2016; Suzuki et al., 2011). A direct correlate
of such observations is that tight regulation of glycogen meta-
bolism, and in particular the maintenance of a releasable glycogen
pool, is crucial to sustain such physiological processes.
As in peripheral organs, cerebral glycogen mobilization and
synthesis is under complex metabolic regulations involving both
allosteric and covalent modiﬁcations and for which glycogen syn-
thase (GS) and glycogen phosphorylase (GP) represent the two
central elements (see e.g. Allaman andMagistretti, 2015; Obel et al.,
2012; Roach et al., 2012). In particular, protein kinase-catalyzed
phosphorylation inactivates GS and activates GP, resulting inicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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whereas dephosphorylation of both enzymes leads to inactivation
of GP and activation of GS allowing synthesis of glycogen from the
precursor UDP-glucose. While phosphorylation of both GS and GP
involves different set of kinases, protein phosphatase-1 (PPP1) is
the enzyme responsible for dephosphorylation of both GS and GP.
In order to be active, PPP1must be bound to glycogen through PPP1
glycogen-binding subunits (Ceulemans et al., 2002; Korrodi-
Gregorio et al., 2014). So far, at least seven distinct glycogen-
binding subunit have been identiﬁed (PPP1R3A to G) which show
speciﬁc cellular and tissue distributions (Ceulemans et al., 2002).
The major ones include PPP1R3A (GM) which is muscle-speciﬁc
(Suzuki et al., 2001), PPP1R3B (GL) which is the primary PPP1R3
expressed in the liver (Doherty et al., 1995), and the relatively
widespread-ubiquitous isoforms PPP1R3C (PPP1R5 or PTG for
protein targeting to glycogen) (Printen et al., 1997) and PPP1R3D
(PPP1R6) (Armstrong et al., 1997). Interestingly, the gene encoding
PTG is abundantly expressed in astrocytes of the CNS (Lovatt et al.,
2007; Zhang et al., 2014), and several lines of evidence suggested
that PTG plays an important role in the regulation of glycogen
metabolism in this cell type (Allaman et al., 2000, 2003; Petit et al.,
2013; Vilchez et al., 2007).
Astrocytic glycogen levels are under tight control by numerous
glycogenolytic and glycogenic neuro-active substances including,
noradrenaline (NA), VIP, insulin (Ins), insulin-growth factors I and
II, glutamate, glucocorticoids, ATP or adenosine (see e.g. Brown,
2004; Magistretti et al., 1993a, 1993b; Obel et al., 2012).
Regarding the maintenance of a releasable glycogen pool, NA and
Ins represent interesting cases since both are known to promote
long-term glycogen synthesis in astrocytes (Allaman et al., 2003;
Dringen and Hamprecht, 1992; Hamai et al., 1999; Heni et al.,
2011; Kum et al., 1992; Sorg and Magistretti, 1992). While NA and
Ins glycogenic effects ultimately involve dephosphorylation and
activation of GS (Allaman et al., 2004; Hamai et al., 1999), the
activation cascades resulting in GS activation differ between the
two agents (cAMP and PI3-kinase cascades for NA and Ins respec-
tively). Interestingly, we have previously shown that NA, but not
Ins, stimulates PTG mRNA expression concomitantly with glycogen
resynthesis, suggesting PTG as the main mediator of glycogen
resynthesis induced by NA.
In this study, we manipulated PTG expression in primary cul-
tures, by up- or down-regulation, to determine its role in the
regulation of glycogen content in astrocytes. Moreover, we aimed to
address PTG involvement in the glycogenic action of NA and Ins.
2. Materials and methods
2.1. Reagents and antibodies
All chemicals and culture mediums, if not otherwise speciﬁed
are from Sigma-Aldrich, Buchs SG, Switzerland.
2.2. Astrocytes cultures
Experiments were conducted in accordance with the Swiss
Federal Guidelines for Animal Experimentation and were approved
by the Cantonal Veterinary Ofﬁce for Animal Experimentation
(Vaud, Switzerland). Primary cultures of cerebral cortical astrocytes
were prepared as previously described (Belanger et al., 2011) from
newborns (1-2 days-old) of OF1 mice (Charles River Laboratories,
L'Arbresle, France) or heterozygous C57/Bl6j PTG KO mice (pro-
duced by A. A. DePaoli-Roach). For PTG KO astrocytic cultures,
newborn pups from heterozygous breedings of C57/Bl6j PTG KO
micewere genotyped by quantitative PCR. From eachwild-type and
knock-out homozygote mice, one littermate was selected perexperiment and brain was dissected for astrocytic cultures. Cells
were plated in 35 mm Ø dishes or glass coverslips and incubated in
culture medium (Dulbecco's Modiﬁed Eagle Medium [DMEM]
containing 25 mM glucose, Sigma-Aldrich, D7777) supplemented
with 10% fetal calf serum, at 37 C in a humidiﬁed atmosphere
containing 5% CO2 and 95% air. The culture medium was renewed
3e5 days after seeding and subsequently twice a week. Experi-
ments were performed on conﬂuent 14 days-old cultures (DIV14)
with the exception of immunoﬂuorescence experiments which
were performed on non-conﬂuent (low density plated) cultures
(DIV14) to facilitate cellular localization of Flag-PTG.
2.3. Small interfering RNA (siRNA) transfection
Speciﬁc PPP1R3C (PTG) downregulation in astrocytes was ach-
ieved using Stealth Select RNAi™ (siRNA, Ref. no. PPP1R3C/
MSS284999; Invitrogen, Basel, Switzerland). Control groups (Mock
siRNA) were transfected with siRNA negative controls (Hi GC
complex #2, Invitrogen). For each 35 mm Ø dish, 100 pmoles siRNA
was transfected following a previously described protocol
(Belanger et al., 2011). Each siRNA was applied to astrocytes for 4
days, followed by Western blot analysis, quantitative PCR and
glycogen determination.
2.4. Adenovirus mediated Flag-PTG overexpression
To infect astrocytes, DIV9 cortical astrocytes (around 80% of
conﬂuency) were incubated in 1 mL serum free DMEM (Sigma-
Aldrich, D5030) supplemented with (ﬁnal concentrations) 5 mM
glucose, 44 mM NaHCO3, 0.06 g/L penicillin and 0.1 g/L strepto-
mycin (DMEM5). 1  106 Pfu of adenovirus containing Flag-tagged
mouse PTG (Ad-Flag-m-PPP1R3C, ADV-269217 clone) or enhanced
GFP (EGFP) (Ad-GFP used as control adenovirus, cat. n 1060) both
under the control of the CMV promoter, obtained by Vector BioLabs
(Philadelphia, USA), were added directly in the dishes and incu-
bated overnight. The next day, DMEM5 medium was replaced by
fresh culture medium. Experiments using adenovirus were con-
ducted in biosafety level 2 laboratory and performed 5 days after
infection. When indicated siRNAs were applied 24 hours after ad-
enoviruses infection following the above-described protocol.
2.5. Cell treatment with noradrenaline and insulin
During all incubations, primary cultures of astrocytes were
maintained at 37 C in a humidiﬁed atmosphere containing 5% CO2
and 95% air. 16 h before treatment, the culture medium was
removed and astrocytes were incubated in serum free DMEM5.
Without changing the medium, the cells were then exposed to
noradrenaline (NA) or Insulin (Ins) for 6 h followed by glycogen
determination. It was previously demonstrated that under these
experimental conditions glucose concentration is not a limiting
factor for glycogen synthesis induced by glycogenic agents
(Allaman et al., 2003, 2004).
2.6. Quantitative PCR (qPCR)
Gene expression analysis: RNA isolation, cDNA synthesis and qPCR
ampliﬁcation were performed as previously described (Belanger
et al., 2011). Forward and reverse sequences were as follows: b-
Actin: 50-GCTTCTTTGCAGCTCCTTCGT-30 and 50-ATATCGTCATC-
CATGGCGAAC-30; Cyclophilin A: 50-CAAATGCTGGACCAAACACAA-30
and 50-GCCATCCAGCCATTCAGTCT-30;Protein phosphatase 1 regula-
tory subunit 3C (PPP1R3C or PTG): 50-GGCATGACGGAACTTGTCAA-30
and 50-TGCCTCTCGGTCCAATGAG-30; Glycogen Synthase 1, muscle
(Gys1): 50-GCTGGACAAGGAGGACTTCACT-30 and 50-
E. Ruchti et al. / IBRO Reports 1 (2016) 46e5348TGCACACTGGTGGGAAAGAC-30; Glycogenin (Gyg): 50-ACACCTTCAC-
CACCAACGTCTT-30 and 50-GCTCCTGAGACATGTTCCATCAT-30; Brain
Glycogen Phosphorylase (Pygb): 50-GCTGCTCAACTGCCTACACATT-30
and 50-AACAGTCCTGGGCACAAAGG-30; Protein phosphatase 1 regu-
latory subunit 3D (PPP1R3D or PPP1R6): 50-GAGGAGGCCTGC-
TATCTGTTTTC-30 and 50-AATGCAGGCCACACTGTGTATC-30.
Genotyping: Genotyping was performed using qPCR. Genomic
DNA was isolated from cerebellum of C57/Bl6j pups using Dneasy
blood and tissue kit (Qiagen, Hombrechtikon, Switzerland) accord-
ing to the manufacturer instructions. PCR mix was composed of
10 ng of genomic DNA, 300 nM of forward and reverse primers in
10 mL of 1x SYBR-Green Fast PCR MasterMix (Applied Biosystems).
Genomic DNA and LoxP sequences for forward and reverse primers
were as follows: b-Actin (NC_000071.6 Chromosome 5): 50-
CCCTTCTCTTTGGCCAGCTT-30 and 50-ACGGCAGAAGAAAGA-
CAATTGAG-30; Ppia (Peptidyl-prolyl cis-trans isomerase):
(NC_000077.6 Chromosome 11) 50-GATCTGTTGACAA-
GAGTGCAAAGC-30 and 50-AGAGGGAATGAAAGGAACACTGAA-30;
PPP1R3C (PTG WT): (NC_000085.6 Chromosome 19): 50-AAATCG-
CAGAGTGAGTGGAAGAG-30 and 50- GCAAACACGACCCGCTTCT-30;
LoxP (PTG KO): 50-CGCGCCAAGCTGTCTAGAAT-30 and 50-GAA-
CAAAGCTGGTGGCATCA-30. Genotypes were identiﬁed from the
relative genomic abundance of PTG and LoxP following normaliza-
tion to b-Actin and Ppia genomic content levels.2.7. Western blot
Protein extraction and detection were performed following a
previously described procedure (Yang et al., 2014). PTG protein
levels were quantiﬁed using the ratio of Flag-tagged PTG/Actin as
detected by chemiluminescence. Antibodies used were: mouse
anti-Flag M2 (Sigma-Aldrich, F1804) (dilution 1/10000), mouse
anti-b-Actin (Sigma-Aldrich, A5441) (dilution 1/100000000) and
mouse horseradish peroxidase-conjugated secondary antibody (GE
Healthcare, Glattburg, Switzerland).2.8. Immunoﬂuorescence and image acquisition
DIV14 astrocytes grown on glass coverslips were ﬁxed with 4%
paraformaldehyde for 10 min, washed 3 times with PBS and per-
meabilized for 10 min in phosphate-buffered saline (PBS) con-
taining 0.1% triton X-100. Coverslips were then incubated in PBS
containing 5% bovine serum albumin and 0.05% triton X-100 for
30 min to block non-speciﬁc binding before incubation with a
monoclonal antibody directed against the Flag epitope (see above,
1/500 dilution) in PBS for 2 h. Glass slides were rinsed thoroughly
and probed with the secondary antibody, anti-mouse Alexa Fluor®
488 (Thermo Fisher Scientiﬁc, Reinach, Switzerland) for 1 h at room
temperature in PBS. After extensive washing, coverslips were
ﬁnally incubated with 0.2 mg/mL Hoechst to stain nuclei, rinsed in
PBS and mounted with an anti-bleaching medium (DABCO). Image
acquisitions were performed as a stack of 10 images with 300 nm
step size on a wide-ﬁled microscope (Leica DM5500) with a
40 1.3 oil immersion objective and recordedwith DFC 350FX B/W
camera. Deconvolution was performed on each image to sharpen
their signal.2.9. Glycogen quantiﬁcation
At the end of incubation periods, the cells were lysed and har-
vested for glycogen quantiﬁcation as previously descried (Allaman
et al., 2000). Glycogen content is expressed as nmoles of glycosyl
units originating from glycogen per mg of protein.2.10. Calcein viability assay
At the end of adenovirus exposure, astrocytic viability was
determined by the calcein assay using a standard procedure (see
e.g. Allaman et al., 2010).
2.11. Statistical analysis
All results are presented as the mean ± SEM and signiﬁcance
was considered at p  0.05 for all statistical tests. Data were
analyzed for statistical signiﬁcance by unpaired Student's t-test or
by one-way ANOVA followed by a Bonferroni's multiple compari-
son test (Prism 5.0, GraphPad, San, Diego, CA).
3. Results
3.1. PTG overexpression leads to massive glycogen accumulation in
cultured astrocytes
As a ﬁrst step to investigate the importance of PTG in controlling
astrocytic glycogen content, the impact of increased PTG expression
was assessed in primary cultures of mouse astrocytes using
adenovirus-mediated overexpression of a Flag-tagged PTG
construct. PTG tagging was chosen to monitor PTG protein
expression levels since the commercially available PTG antibodies
did not produce a speciﬁc signal in our hands. Five days following
culture infection, adenovirus-mediated overexpression of PTG
resulted in a 67-fold increase in PTG mRNA levels, as compared to
control cultures infected with an adenovirus overexpressing the
EGFP protein, whereas mRNA expression of other important genes
related to astrocytic glycogen metabolism were not signiﬁcantly
affected. Tested genes included the brain isoform of glycogen
phosphorylase (Pygb), muscle isoform of glycogen synthase (Gys1),
glycogenin (Gyg), as well as another PPP1 glycogen binding sub-
unit, PPP1R3D (or PPP1R6) (Fig. 1A).
PTG mRNA correlated with increased protein levels as deter-
mined by Western blot analysis and immunohistochemistry using
an antibody directed against the Flag (Fig. 1B and C). At the sub-
cellular level, the exogenous Flag-tagged PTG showed a punctate
pattern that was homogeneously distributed in the cytoplasm,
which is consistent with previously reported glycogen and
glycogen synthase distribution patterns in cultured astrocytes
(Vilchez et al., 2007).
To examine the physiological consequence of Flag-tagged PTG
overexpression, we measured astrocyte glycogen content. As
shown in Fig. 1D, cells overexpressing PTG present a remarkable
glycogen accumulation (more than 100-fold increase), demon-
strating that increased PTG expression was sufﬁcient to drive
glycogen metabolism into a synthetic mode in this cell type.
Of note, control experiments demonstrated the lack of cellular
toxicity (as measured with the cell viability calcein assay) of
adenovirus-mediated PTG overexpression and the associated
glycogen accumulation in cultured astrocytes in our experimental
conditions (not shown).
3.2. PTG downregulation decreases the glycogenic ability in
astrocytes
As a mirror experiment to PTG overexpression, the impact of
PTG downregulation on glycogen content was tested in cultured
astrocytes using short interfering RNA (siRNA) directed against
PTG. PTG silencing efﬁciency and speciﬁcity were assessed by
quantitative PCR and Western blot after four days of siRNA treat-
ment (Fig. 2A and B). As shown in Fig. 2A, PTG mRNA levels were
decreased by 60.0 ± 2.2% in PTG siRNA transfected astrocytes
Fig. 1. PTG overexpression increases glycogen content in cultured astrocytes. Primary
cultures of mouse astrocytes were infected with adenovirus containing Flag-tagged
mouse PTG (Flag-PTG), or enhanced GFP (EGFP) as control, for ﬁve days. (A) mRNA
expression levels of genes related to astrocytic glycogen metabolism. Data are
means ± SEM and expressed as percentage of the EGFP values for each gene
(n ¼ 12e14, 4e5 independent experiments). (B) Representative Western blot of Flag-
PTG protein detection (actin as a loading control). Similar results were obtained in 5
independent experiments. (C) Representative immunostaining of Flag-PTG, with (C1)
and without (C2) nuclear staining with Hoechst. No Flag-PTG staining was observed in
the nuclei. Similar results were obtained in 2 independent experiments. (D) Glycogen
content. Data are means ± SEM and are expressed as nmoles of glycosyl units per mg of
proteins (n ¼ 12, 4 independent experiments). ***P  0.001 vs respective EGFP con-
ditions with ANOVA followed by Bonferroni's post hoc test (A), or unpaired t-test (D).
Pygb, brain glycogen phosphorylase; Gys1, muscle glycogen synthase 1; Gyg, glycogenin;
PPP1R6 (or PPP1R3D), Protein phosphatase 1 regulatory subunit 3D; PTG (or PPP1R3C),
Protein phosphatase 1 regulatory subunit 3C.
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expression levels of other astrocytic glycogen-related genes
remained unaltered. Efﬁciency of siRNA-mediated downregulation
of PTG protein was demonstrated in cultured astrocytes over-
expressing Flag-tagged PTG (see above) for which a 75.0 ± 4.6%
reduction in protein expression following siRNA co-treatment was
estimated (Fig. 2B, left and middle panels); this effect was associ-
ated with a strong reduction in glycogen accumulation (63.5 ± 2.6%
decrease; Fig. 2B, right panel). Basal astrocytic glycogen content
when PTG expressionwas downregulated resulted in a 50.7 ± 10.4%
decrease compared to control values (mean ± SEM; n ¼ 19e21, 7
independent experiments; Student's t-test: p  0.0001), furtherestablishing the importance of PTG in the regulation of basal
glycogen levels in astrocytes.
The impact of siRNA-mediated PTG downregulation was then
assessed on the glycogenic actions of both noradrenaline (NA) and
insulin (Ins), two well characterized regulators of glycogen syn-
thesis in astrocytes (Hamai et al., 1999; Heni et al., 2011; Sorg and
Magistretti, 1992). Considering that increased PTG expression was
previously shown to be associated with the glycogenic action of NA,
but not Ins, one might have assumed that PTG downregulation
would speciﬁcally impair NA-induced glycogen synthesis (Allaman
et al., 2000). Indeed, a strong reduction in the fold increase of NA-
stimulated glycogen synthesis following PTG downregulation could
be observed (23.3 and 6.1 fold increase in mock and PTG siRNA
conditions, respectively; Fig. 2C). Surprisingly however, Ins-
stimulated glycogen synthesis was also found to be signiﬁcantly
reduced by PTG downregulation (5.3 and 2.3 fold increase in mock
and PTG siRNA conditions, respectively; Fig. 2C). These ﬁndings
suggest that PTG is a key element in the glycogenic actions of both
NA and Ins in astrocytes.
We next determined the impact of a complete loss of function of
PTG in the regulation of glycogen metabolism using knock-out
mice. Astrocytic cultures prepared from PTG KO mice similarly to
siRNA PTG treated cultures displayed no compensatory changes in
mRNA expression levels of Pygb, Gys1, Gyg or PPP1R6 (Fig. 3A) but
exhibited a robust reduction of their glycogen pool size, i.e. a
80.3 ± 5.4% decrease compared to wild-type (WT) control litter-
mate cultures (mean ± SEM; n ¼ 12, 4 independent experiments;
Student's t-test: p 0.0001). Most importantly, we observed that in
PTG KO cultures, NA and Ins were unable to promote glycogen
synthesis. These observations further conﬁrm the results obtained
by PTG downregulation by siRNA and suggest that PTG is an
essential element for the glycogenic actions of both neurochemical
and humoral factors (Fig. 3B).4. Discussion
PPP1-targeting subunits are key regulators of glycogen synthe-
sis in mammalian cells. Here, we report that one of its members,
PTG, plays a major role in glycogen metabolism regulation in as-
trocytes under both basal and glycogen synthesis stimulating
conditions. By manipulating PTG expression levels in primary
astrocyte cultures either by adenovirus-mediated overexpression
of PTG or siRNA-mediated downregulation of its expression as well
as using PTG KO cultured astrocytes, a direct correlation between
PTG proteins levels in astrocyte and glycogen synthesis could be
established.
PPP1-glycogen targeting regulatory subunits (PPP1R3s) are
scaffolding protein which co-localize the catalytic subunit of PPP1
(PPP1c) with speciﬁc glycogen-metabolic enzymes, enabling
dephosphorylation of GS and GP hence ﬁne-tuning glycogen syn-
thesis ﬂux. As PTG is highly expressed in astrocytes (Lovatt et al.,
2007; Zhang et al., 2014) it represented a possible candidate as a
regulator of glycogen synthesis in this cell type. Indeed, our results
show that manipulating PTG levels (up or down) in astrocytes had a
consistent and direct effect on glycogen content: i) overexpression
of PTG led to a 100 fold increase in glycogen ii) the effects of PTG
expression on protein levels and glycogen accumulation were
counteracted by siRNA treatment to the same extent (75 and 63%
decrease respectively) iii) downregulation of endogenous PTG
expression by siRNA led to a 2 fold decrease in glycogen iv) ablation
of PTG expression (PTG KO astrocytes) led to a 80% decrease in
glycogen. No alteration or compensatory changes of expression of
other genes involved in astrocytic glycogen metabolism was
Fig. 2. Effects of RNA interference against PTG on glycogen metabolism regulation.
Cultured astrocytes were transfected with siRNA against PTG or a negative control
siRNA (mock siRNA) for four days. (A) mRNA expression levels of genes related to
astrocytic glycogen metabolism. Data are means ± SEM and expressed as percentage of
the mock siRNA values for each gene (n ¼ 6e7, 2e3 independent experiments).
***P  0.001 vs mock siRNA condition with ANOVA followed by Bonferroni's post hoc
test. (B) Downregulation of adenovirus-mediated overexpression of Flag-PTG protein
by PTG siRNA. (left panel) Representative Western blot for Flag-PTG protein detection
(actin as a loading control). (middle panel) Quantiﬁcation of Western blots as shown
on the left panel following normalization by actin content (n ¼ 10, 5 independent
experiments). (right panel) Glycogen content (n ¼ 12, 4 independent experiments).
Data are means ± SEM expressed as percentage of respective mock siRNA control
conditions. ***p  0.001 vs mock siRNA with unpaired t-test. (C) Glycogen content
following noradrenaline (NA, 100 mM) and Insulin (Ins, 100 nM) treatments for 6 h
(n ¼ 10e12, 4 independent experiments). Data are means ± SEM and expressed as
percentage of the mock siRNA untreated condition (Ctr). ***p  0.001 vs Ctr and
###p  0.001 vs respective mock siRNA conditions with ANOVA followed by Bon-
ferroni's post-hoc test for NA conditions comparison (including Ctrl and NA, in mock
and PTG siRNA conditions), respectively Ins conditions comparison (including Ctrl and
Ins, in mock and PTG siRNA conditions).
Fig. 3. Glycogen metabolism regulation in astrocytic PTG KO cultures. Cultured as-
trocytes were isolated from PTG KO mice (PTG-KO) or wild-type (WT) littermates. (A)
mRNA expression levels of genes related to astrocytic glycogen metabolism. Data are
means ± SEM and expressed as percentage of the WT values for each gene (n ¼ 12, 4
independent experiments). ***P  0.001 vs WT condition with ANOVA followed by
Bonferroni's post hoc test. (B) Glycogen content following NA (100 mM) and Ins
(100 nM) treatments for 6 h (n ¼ 11e12, 4 independent experiments). Data are
means ± SEM and expressed as percentage of the WT untreated condition (Ctr).
***p  0.001 vs Ctr and ###p  0.001 vs respective mock siRNA conditions with
ANOVA followed by Bonferroni's post-hoc test for NA conditions comparison
(including Ctrl and NA, in mock and PTG siRNA conditions), respectively Ins conditions
comparison (including Ctrl and Ins, in mock and PTG siRNA conditions).
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reinforcing the notion that the observed changes in glycogen
metabolism were directly produced by changes in PTG expression.These observations, i.e the close correlation between PTG
expression and glycogen levels, are fully consistent with other re-
ports showing that PTG overexpression leads to glycogen accu-
mulation (i.e. associated with increased GS activity and decreased
GP activity) in different cell types in cultures, such as rat hepato-
cytes, human muscle cells, 3T3-L1 adipocytes (Berman et al., 1998;
Gasa et al., 2000; Greenberg et al., 2006; Lerin et al., 2000; Montori-
Grau et al., 2011), whereas siRNA-mediated downregulation of PTG
strongly reduces basal glycogen levels (Greenberg et al., 2006).
Similarly, in vivo targeted overexpression of PTG in beta-cells of the
pancreas, adipose tissue or liver also results in glycogen accumu-
lation (Jurczak et al., 2007; Mir-Coll et al., 2016; O'Doherty et al.,
2000) while heterozygous or homozygous PTG deletion in mice
have decreased glycogen tissue levels in muscles, liver, adipose or
brain tissues (Crosson et al., 2003; Turnbull et al., 2011, 2014).
Altogether, these results demonstrate that PTG expression levels
are key determinants for glycogen synthesis and accumulation in
astrocytes as in other PTG-expressing cell types. Interestingly, in
PTG KO mice the decrease in glycogen levels in the brain (70%) is
more pronounced than in muscle (30%) further supporting the
notion that PTG expression is a prevalent regulator of glycogen
synthesis in brain both in vitro and in vivo (Turnbull et al., 2011).
NA and Ins are two well established regulators of glycogen
metabolism in astrocytes involving the activation of different
metabolic pathways. For instance, NA exerts a biphasic effect on
glycogen levels (Allaman et al., 2003; Sorg and Magistretti, 1991,
E. Ruchti et al. / IBRO Reports 1 (2016) 46e53 511992) i.e. a rapid glycogen mobilization induced by this neuro-
transmitter (involving both alpha- and beta-adrenergic receptors)
followed by a delayed and massive glycogen resynthesis (taking
place hours after stimulation), therefore coupling glycogen mobi-
lization to the subsequent replenishment of glycogen reserves.
Importantly, this long term glycogen resynthesis, which critically
depends upon the activation of the cAMP signaling cascade (hence
activation of beta-adrenergic receptors) and synthesis of new
proteins, is accompanied by dephosphorylation and activation of
GS which occurs concomitantly with increased PTG mRNA levels
(Allaman et al., 2000, 2004; Sorg and Magistretti, 1992). As for NA,
other cAMP cascade activators, such as VIP and adenosine, repro-
duce the effect of NA on glycogen synthesis and PTG mRNA sug-
gesting a common mechanism of action on astrocytic glycogen
metabolism (Allaman et al., 2000, 2003; Sorg and Magistretti,
1992). Ins also promotes long-term glycogen synthesis in astro-
cytes but in contrast to NA its effect is unidirectional (i.e. no
glycogenolysis is elicited) (Hamai et al., 1999; Heni et al., 2011; Sorg
andMagistretti, 1992). Of note, Ins-stimulated glycogen synthesis is
time-dependent occurring within 2 h and maintained over time
(Sorg and Magistretti, 1992). This long-term effect is, as for NA,
protein synthesis dependent which contrasts with the rapid, within
minutes, activation of GS induced by Ins in vivo in peripheral tis-
sues (see e.g. Crosson et al., 2003). The glycogenic action of Ins in
astrocytes involves the activation of GS through a PI3-kinase-
dependent pathway and has not been associated with changes in
PTG expression (Allaman et al., 2000; Hamai et al., 1999; Heni et al.,
2011).
The different glycogenic activation proﬁles of NA and Ins on GS
activation and PTG mRNA expression suggested a different mech-
anism for regulation of GS. Glycogen synthesis induced by NA was
strongly reduced by PTG siRNA treatment in astrocytes and fully
abolished in PTG KO astrocytes, establishing that PTG is a necessary
mediator to account for glycogen synthesis induced by NA. How-
ever, our results also demonstrated that Ins effects on glycogen
synthesis are reduced in astrocytes in which PTG was down-
regulated and was fully prevented in PTG KO astrocytes. Other
glycogen-binding subunits such as PPP1R3A and 3B are not
expressed in astrocytes or in brain (Doherty et al., 1995; Lanner
et al., 2001; Zhang et al., 2014) suggesting that Ins action in as-
trocytes, as opposed to peripheral tissues, may rely more on PTG.
PTG KO astrocytes, as well as brains of PTG KO mice (Turnbull
et al., 2011, 2014), still contain signiﬁcant glycogen levels, even
though strongly reduced, implying the existence of additional and
active PPP1R3s-dependent glycogen regulatory mechanisms to
PTG. Interestingly, the reduction in glycogen content measured in
astrocytes (80%, this study) is similar to the one observed in brains
of PTG KO mice (70%) (Turnbull et al., 2011), further indicating a
close parallel between glycogen metabolism in cultured astrocytes
and brain glycogen metabolism. Here we demonstrate that PPP1R6,
another glycogen-binding subunit which is known to be expressed
in brain (Armstrong et al., 1997), is also expressed in cultured as-
trocytes and that its transcriptional expression levels are not
altered by PTG overexpression, silencing or in KO mice. Neverthe-
less, PPP1R6, or other putative targeting subunits expressed in
cultured astrocytes, were unable to counteract the drastic effects of
PTG silencing on basal and NA- and Ins-stimulated glycogen syn-
thesis in astrocytes. While the exact role played by PPP1R6 on
astrocytic glycogen metabolism remains to be fully established,
these observations indicate a lack of redundancy between PPP1R6
and PTG functions. PPP1R6 was recently shown to be regulated by
14-3-3 proteins which interact with PPP1R6 through a consensus
motif for 14-3-3 protein binding that is not present in other gly-
cogenic subunits including PTG, arguing in favor of such view
(Rubio-Villena et al., 2015). Of note, as PTG KO mice were fullyviable (Turnbull et al., 2011, 2014) this indicates that the control of
glycogen metabolism by PPP1R6, and possibly by other recently
identiﬁed glycogen-binding subunits expressed in brain such as
PPP1R3F (Kelsall et al., 2011) and 3G (Zhang et al., 2014), can sustain
normal brain functions in the absence of PTG. However, brain
functions could be affected not only by glycogen levels but also by
glycogen turnover (see e.g. Obel et al., 2012), which could be altered
by the absence of PTG.
While most of the characterization of NA and Ins glycogenic
effects were obtained from studies performed on in vitro or ex vivo
preparations there are strong indications that similar regulation of
glycogen metabolism by NA and Ins may also operate in vivo. For
instance, astrocytes express both alpha- and beta-noradrenergic
receptors and can therefore respond to noradrenergic stimula-
tion, hence modifying their glycogen metabolism (Stone and
Ariano, 1989). In particular, a role in beta-adrenergic-induced
glycogen mobilization in learning and memory in chick has been
well documented (Gibbs, 2016). For Ins, Ins receptors are widely
distributed throughout the CNS (Havrankova et al., 1978) and are
also found in astrocytes (Heni et al., 2011; Zhu et al., 1990). A
general consensus is that little or no Ins is produced in the brain;
however, Ins can enter the brain via circumventricular regions that
lack a tight blood-brain barrier or via a receptor-mediated active
transport system (Banks, 2004; Baskin et al., 1987; Weindl and
Sofroniew, 1981).
Altogether, these observations indicate that in the absence of
PTG, glycogen synthesis induced by NA and Ins is impaired and that
the amplitude of the effects of NA (as well as VIP and adenosine)
and Ins on glycogen synthesis are directly correlated to PTG
expression levels.
Expression of PTG is known to be regulated by different factors.
As previously stated, in astrocytes activators of the cAMP pathways,
such as NA, VIP or adenosine, upregulate PTG mRNA expression in
astrocytes (Allaman et al., 2000, 2003), through a transcriptional
mechanism most probably involving the activation of C/EBP tran-
scription factors (Allaman et al., 2000; Cardinaux and Magistretti,
1996). Glucose was shown to regulate PTG expression in hepato-
cytes through a MondoA-dependent mechanism (Petrie et al.,
2013). In addition, PTG expression was also shown to be
controlled by Per2, BMAL-1, FoxA2, SREBP, Hif1alpha transcrip-
tional regulators (Cheng et al., 2006; Lu et al., 2014; Shen et al.,
2010; Zani et al., 2013). Interestingly, Ins induced PTG mRNA
expression in cultured hepatocytes (Petrie et al., 2013) but not in
cultured astrocytes (Allaman et al., 2000), highlighting the exis-
tence of tissues speciﬁc regulation of PTG. Such factors may directly
participate in the regulation of PTG expression in different condi-
tions and therefore impact cerebral glycogen metabolism.
While glycogen metabolism is primarily associated with astro-
cytes it is well established that its use does not only beneﬁt as-
trocytes but also the surrounding neurons. For instance, glycogen
mobilization preserves neuronal viability in energy delivery failure
conditions, such as in hypoxia or glucose deprivation, in a variety of
models (see e.g. Magistretti and Allaman, 2015 and references
therein). More recent evidence demonstrated that glycogen is
important to sustain higher brain functions such as learning and
memory in different experimental paradigms (Boury-Jamot et al.,
2016; Duran et al., 2013; Gao et al., 2016; Gibbs, 2016; Newman
et al., 2011; Obel et al., 2012; Suzuki et al., 2011). Learning and
memory abilities as well as the establishment of long-term
potentiation in vivo are altered by pharmacological blockade of
glycogen mobilization in rodents or in a brain-speciﬁc glycogen
synthase knockout (GYS1Nestin-KO) mouse model that lack
glycogen (Boury-Jamot et al., 2016; Duran et al., 2013; Newman
et al., 2011; Suzuki et al., 2011). Determination of the mecha-
nisms involved in the latter effects demonstrated that they critically
E. Ruchti et al. / IBRO Reports 1 (2016) 46e5352dependent on the transfer of glycogen-derived astrocytic lactate to
neurons (Boury-Jamot et al., 2016; Newman et al., 2011; Suzuki
et al., 2011). This implies that the maintenance of a readily releas-
able glycogen pool is of importance to sustain astrocytic-dependent
neuronal plasticity. The present work highlights PTG as a master
regulator of astrocytic glycogen placing PTG, as well as PTG regu-
lation, as a central element in glycogen regulation in vivo. Inter-
estingly, changes in cerebral PTG mRNA expression have been
demonstrated in different behavioral conditions known to involve
glycogen mobilization, such as sleep deprivation and learning and
memory (Petit et al., 2002, 2010; Tadi et al., 2015). A strong
reduction of PTG mRNA expression, which was coupled to an
altered glycogen metabolism, was also observed in cultured as-
trocytes isolated from GCLM KO mice, a mouse model of schizo-
phrenia (Lavoie et al., 2011). As a whole these observations argue in
favor of a critical role of PTG in the control of cerebral glycogen
metabolism, hence astrocytic functions, in both physiological and
pathological conditions, such as psychiatric disorders. Undoubt-
edly, detailed phenotypical and behavioral characterization of PTG
KO mice will contribute to the understanding of the exact role by
PTG in these processes.
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